In yesterday’s Wall Street session, Selecta Biosciences Inc. (NASDAQ:SELB) shares traded at $0.96, down -2.55% from the previous session.
8 analysts cover Selecta Biosciences Inc. (NASDAQ:SELB), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $4.00, we find $7.00. Given the previous closing price of $0.98, this indicates a potential upside of 614.29 percent. SELB stock price is now -31.92% away from the 50-day moving average and -33.05% away from the 200-day moving average. The market capitalization of the company currently stands at $152.14M.
The stock has received a hold rating from 0 analysts and a buy rating from 8. Brokers who have rated the stock have averaged $6.86 as their price target over the next twelve months.
With the price target reduced from $6 to $5, Needham maintained Buy rating for Selecta Biosciences Inc. (NASDAQ: SELB). On June 06, 2022, SVB Leerink recently initiated its ‘Outperform’ rating on the stock quoting a target price of $7, while ‘BTIG Research’ rates the stock as ‘Buy’.
In other news, Brunn Carsten, President and CEO sold 4,522 shares of the company’s stock on Dec 05. The stock was sold for $6,014 at an average price of $1.33. Upon completion of the transaction, the President and CEO now directly owns 544,283 shares in the company, valued at $0.52 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 28, President and CEO Brunn Carsten sold 2,692 shares of the business’s stock. A total of $4,470 was realized by selling the stock at an average price of $1.66. This leaves the insider owning 537,867 shares of the company worth $0.52 million. Insiders disposed of 41,080 shares of company stock worth roughly $39436.799999999996 over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SELB stock. A new stake in Selecta Biosciences Inc. shares was purchased by BANK OF MONTREAL /CAN/ during the first quarter worth $1,007,000. HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND invested $688,000 in shares of SELB during the first quarter. In the first quarter, DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT acquired a new stake in Selecta Biosciences Inc. valued at approximately $504,000. ALLY BRIDGE GROUP (NY) LLC acquired a new stake in SELB for approximately $319,000. FIRST TRUST ADVISORS LP purchased a new stake in SELB valued at around $288,000 in the second quarter. In total, there are 119 active investors with 48.80% ownership of the company’s stock.
On Tuesday morning Selecta Biosciences Inc. (NASDAQ: SELB) stock kicked off with the opening price of $0.9800. During the past 12 months, Selecta Biosciences Inc. has had a low of $0.65 and a high of $3.58. As of last week, the company has a debt-to-equity ratio of 0.31, a current ratio of 6.70, and a quick ratio of 6.70. The fifty day moving average price for SELB is $1.4029 and a two-hundred day moving average price translates $1.4265 for the stock.
The latest earnings results from Selecta Biosciences Inc. (NASDAQ: SELB) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at $0.06, beating analysts’ expectations of -$0.08 by 0.14. This compares to -$0.16 EPS in the same period last year. The net profit margin was 33.70% and return on equity was 66.00% for SELB. The company reported revenue of $20.71 million for the quarter, compared to $24.43 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -15.22 percent. For the current quarter, analysts expect SELB to generate $25.21M in revenue.
Selecta Biosciences Inc.(SELB) Company Profile
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.